Cidara Therapeutics (CDTX) Stock Forecast, Price Target & Predictions
CDTX Stock Forecast
Cidara Therapeutics stock forecast is as follows: an average price target of $24.00 (represents a 84.19% upside from CDTX’s last price of $13.03) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
CDTX Price Target
The average price target for Cidara Therapeutics (CDTX) is $24.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $24.00. This represents a potential 84.19% upside from CDTX's last price of $13.03.
CDTX Analyst Ratings
According to 2 Wall Street analysts, Cidara Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CDTX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cidara Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 14, 2024 | Ed Arce | H.C. Wainwright | $24.00 | $12.86 | 86.63% | 84.19% |
The latest Cidara Therapeutics stock forecast, released on Aug 14, 2024 by Ed Arce from H.C. Wainwright, set a price target of $24.00, which represents a 86.63% increase from the stock price at the time of the forecast ($12.86), and a 84.19% increase from CDTX last price ($13.03).
Cidara Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $24.00 | $24.00 |
| Last Closing Price | $13.03 | $13.03 | $13.03 |
| Upside/Downside | -100.00% | 84.19% | 84.19% |
In the current month, the average price target of Cidara Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cidara Therapeutics's last price of $13.03. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | H.C. Wainwright | - | Buy | Upgrade |
| May 12, 2022 | Needham | Buy | Buy | Hold |
Cidara Therapeutics's last stock rating was published by H.C. Wainwright on Aug 14, 2024. The company Upgrade its CDTX rating from "null" to "Buy".
Cidara Therapeutics Financial Forecast
Cidara Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $12.72M | $7.61M | $25.99M | $10.22M | $40.74M | $6.22M | $7.11M | $7.22M | $7.08M | $32.86M | $2.41M | $3.73M | $2.42M | $3.39M | $2.53M | $1.81M | $19.10M |
| Avg Forecast | $405.44K | $386.01K | $367.52K | $349.92K | $400.00K | $433.33K | $1.30M | $9.03M | $13.95M | $8.14M | $11.55M | $18.68M | $10.57M | $28.35M | $6.21M | $5.89M | $4.31M | $2.94M | $12.13M | $7.88M | $12.95M | $4.89M | $5.29M | $2.25M | $3.63M | $7.50M |
| High Forecast | $405.44K | $386.01K | $367.52K | $349.92K | $400.00K | $435.00K | $1.30M | $9.03M | $13.95M | $8.14M | $11.55M | $18.68M | $10.57M | $28.35M | $6.21M | $5.89M | $4.31M | $2.94M | $12.13M | $7.88M | $12.95M | $4.89M | $5.29M | $2.25M | $3.63M | $7.50M |
| Low Forecast | $405.44K | $386.01K | $367.52K | $349.92K | $400.00K | $431.67K | $1.30M | $9.03M | $13.95M | $8.14M | $11.55M | $18.68M | $10.57M | $28.35M | $6.21M | $5.89M | $4.31M | $2.94M | $12.13M | $7.88M | $12.95M | $4.89M | $5.29M | $2.25M | $3.63M | $7.50M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.56% | 0.66% | 1.39% | 0.97% | 1.44% | 1.00% | 1.21% | 1.68% | 2.41% | 2.71% | 0.31% | 0.29% | 0.49% | 0.64% | 1.12% | 0.50% | 2.55% |
Cidara Therapeutics's average Quarter revenue forecast for Dec 23 based on 2 analysts is $13.95M, with a low forecast of $13.95M, and a high forecast of $13.95M. CDTX's average Quarter revenue forecast represents a 9.69% increase compared to the company's last Quarter revenue of $12.72M (Sep 23).
Cidara Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-8.55M | $-12.83M | $2.98M | $-13.27M | $15.23M | $-12.81M | $-17.96M | $-18.19M | $-17.99M | $10.82M | $-18.23M | $-21.57M | $-17.56M | $-18.23M | $-14.47M | $-13.95M | $3.12M |
| Avg Forecast | $-299.69K | $-285.34K | $-271.67K | $-258.65K | $-295.67K | $-320.31K | $-960.94K | $-16.79M | $-10.31M | $-6.02M | $-8.53M | $-17.95M | $-17.15M | $-20.95M | $-4.59M | $-19.20M | $-3.19M | $-2.17M | $-8.96M | $-10.03M | $-9.57M | $-3.61M | $-3.91M | $-9.36M | $-2.69M | $-5.54M |
| High Forecast | $-299.69K | $-285.34K | $-271.67K | $-258.65K | $-295.67K | $-319.08K | $-960.94K | $-13.43M | $-10.31M | $-6.02M | $-8.53M | $-14.36M | $-13.72M | $-20.95M | $-4.59M | $-15.36M | $-3.19M | $-2.17M | $-8.96M | $-8.02M | $-9.57M | $-3.61M | $-3.91M | $-7.49M | $-2.69M | $-5.54M |
| Low Forecast | $-299.69K | $-285.34K | $-271.67K | $-258.65K | $-295.67K | $-321.55K | $-960.94K | $-20.15M | $-10.31M | $-6.02M | $-8.53M | $-21.55M | $-20.58M | $-20.95M | $-4.59M | $-23.04M | $-3.19M | $-2.17M | $-8.96M | $-12.04M | $-9.57M | $-3.61M | $-3.91M | $-11.23M | $-2.69M | $-5.54M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.42% | 1.50% | -0.17% | 0.77% | -0.73% | 2.79% | 0.94% | 5.71% | 8.27% | -1.21% | 1.82% | 2.25% | 4.86% | 4.67% | 1.55% | 5.19% | -0.56% |
1 analysts predict CDTX's average Quarter EBITDA for Jun 23 to be $-8.53M, with a high of $-8.53M and a low of $-8.53M. This is -386.69% lower than Cidara Therapeutics's previous annual EBITDA (Mar 23) of $2.98M.
Cidara Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | $-8.17M | $-12.36M | $3.21M | $-13.38M | $14.98M | $-13.13M | $-18.30M | $-16.84M | $-18.08M | $10.71M | $-18.29M | $-21.63M | $-17.63M | $-18.31M | $-14.54M | $-14.02M | $3.04M |
| Avg Forecast | $-7.85M | $-14.88M | $-18.62M | $-21.27M | $-17.13M | $-19.40M | $-18.71M | $-17.08M | $-6.85M | $-13.69M | $-11.87M | $-18.27M | $-17.21M | $-547.65K | $-25.56M | $-19.54M | $-29.66M | $-33.01M | $-19.78M | $-10.06M | $-21.91M | $-36.83M | $-25.64M | $-9.41M | $-39.47M | $-51.41M |
| High Forecast | $-7.85M | $-14.88M | $-18.62M | $-21.27M | $-17.13M | $-19.40M | $-18.71M | $-13.67M | $-6.85M | $-13.69M | $-11.87M | $-14.62M | $-13.76M | $-547.65K | $-25.56M | $-15.63M | $-29.66M | $-33.01M | $-19.78M | $-8.05M | $-21.91M | $-36.83M | $-25.64M | $-7.53M | $-39.47M | $-51.41M |
| Low Forecast | $-7.85M | $-14.88M | $-18.62M | $-21.27M | $-17.13M | $-19.40M | $-18.71M | $-20.50M | $-6.85M | $-13.69M | $-11.87M | $-21.93M | $-20.65M | $-547.65K | $-25.56M | $-23.45M | $-29.66M | $-33.01M | $-19.78M | $-12.07M | $-21.91M | $-36.83M | $-25.64M | $-11.29M | $-39.47M | $-51.41M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.60% | 1.04% | -0.18% | 0.78% | -27.35% | 0.51% | 0.94% | 0.57% | 0.55% | -0.54% | 1.82% | 0.99% | 0.48% | 0.71% | 1.55% | 0.36% | -0.06% |
Cidara Therapeutics's average Quarter net income forecast for Jun 23 is $-11.87M, with a range of $-11.87M to $-11.87M. CDTX's average Quarter net income forecast represents a -469.77% decrease compared to the company's last Quarter net income of $3.21M (Mar 23).
Cidara Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | $3.56M | $3.31M | $4.30M | $3.43M | $5.78M | $4.07M | $5.20M | $4.98M | $4.61M | $4.37M | $4.78M | $4.15M | $3.69M | $3.97M | $4.09M | $4.41M | $4.57M |
| Avg Forecast | $247.03K | $235.19K | $223.92K | $213.20K | $243.71K | $264.02K | $792.07K | $4.86M | $8.50M | $4.96M | $7.03M | $5.20M | $3.30M | $17.27M | $3.78M | $5.56M | $2.63M | $1.79M | $7.39M | $2.63M | $7.89M | $2.98M | $3.22M | $1.37M | $2.21M | $4.57M |
| High Forecast | $247.03K | $235.19K | $223.92K | $213.20K | $243.71K | $265.04K | $792.07K | $5.84M | $8.50M | $4.96M | $7.03M | $6.24M | $3.96M | $17.27M | $3.78M | $6.68M | $2.63M | $1.79M | $7.39M | $3.16M | $7.89M | $2.98M | $3.22M | $1.37M | $2.21M | $4.57M |
| Low Forecast | $247.03K | $235.19K | $223.92K | $213.20K | $243.71K | $263.00K | $792.07K | $3.89M | $8.50M | $4.96M | $7.03M | $4.16M | $2.64M | $17.27M | $3.78M | $4.45M | $2.63M | $1.79M | $7.39M | $2.10M | $7.89M | $2.98M | $3.22M | $1.37M | $2.21M | $4.57M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.72% | 0.47% | 0.83% | 1.04% | 0.33% | 1.08% | 0.94% | 1.90% | 2.57% | 0.59% | 1.82% | 0.53% | 1.24% | 1.23% | 2.99% | 1.99% | 1.00% |
Cidara Therapeutics's average Quarter SG&A projection for Dec 23 is $8.50M, based on 2 Wall Street analysts, with a range of $8.50M to $8.50M. The forecast indicates a 139.02% rise compared to CDTX last annual SG&A of $3.56M (Sep 23).
Cidara Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.09 | $-0.14 | $0.03 | $-0.19 | $0.17 | $-0.19 | $-0.27 | $-0.26 | $-0.37 | $0.18 | $-0.39 | $-0.50 | $-0.41 | $-0.45 | $-0.46 | $-0.42 | $0.08 |
| Avg Forecast | $-1.72 | $-3.26 | $-4.08 | $-4.66 | $-3.75 | $-4.25 | $-4.10 | $-2.39 | $-1.50 | $-3.00 | $-2.60 | $-0.73 | $-2.93 | $-0.12 | $-5.60 | $-5.56 | $-6.50 | $-7.23 | $-4.33 | $-6.70 | $-4.80 | $-8.07 | $-5.62 | $-6.80 | $-8.65 | $-11.27 |
| High Forecast | $-1.72 | $-3.26 | $-4.08 | $-4.66 | $-3.75 | $-4.25 | $-4.10 | $-2.39 | $-1.50 | $-3.00 | $-2.60 | $-0.73 | $-2.93 | $-0.12 | $-5.60 | $-5.56 | $-6.50 | $-7.23 | $-4.33 | $-6.70 | $-4.80 | $-8.07 | $-5.62 | $-6.80 | $-8.65 | $-11.27 |
| Low Forecast | $-1.72 | $-3.26 | $-4.08 | $-4.66 | $-3.75 | $-4.25 | $-4.10 | $-2.39 | $-1.50 | $-3.00 | $-2.60 | $-0.73 | $-2.93 | $-0.12 | $-5.60 | $-5.56 | $-6.50 | $-7.23 | $-4.33 | $-6.70 | $-4.80 | $-8.07 | $-5.62 | $-6.80 | $-8.65 | $-11.27 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.03% | 0.05% | -0.04% | 0.06% | -1.42% | 0.03% | 0.05% | 0.04% | 0.05% | -0.04% | 0.06% | 0.10% | 0.05% | 0.08% | 0.07% | 0.05% | -0.01% |
According to 1 Wall Street analysts, Cidara Therapeutics's projected average Quarter EPS for Jun 23 is $-2.60, with a low estimate of $-2.60 and a high estimate of $-2.60. This represents a -8766.67% decrease compared to CDTX previous annual EPS of $0.03 (Mar 23).
CDTX Forecast FAQ
Is Cidara Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Cidara Therapeutics (CDTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of CDTX's total ratings.
What is CDTX's price target?
Cidara Therapeutics (CDTX) average price target is $24 with a range of $24 to $24, implying a 84.19% from its last price of $13.03. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cidara Therapeutics stock go up soon?
According to Wall Street analysts' prediction for CDTX stock, the company can go up by 84.19% (from the last price of $13.03 to the average price target of $24), up by 84.19% based on the highest stock price target, and up by 84.19% based on the lowest stock price target.
Can Cidara Therapeutics stock reach $20?
CDTX's average twelve months analyst stock price target of $24 supports the claim that Cidara Therapeutics can reach $20 in the near future.
What are Cidara Therapeutics's analysts' financial forecasts?
Cidara Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $11.17M (high $11.17M, low $11.16M), average EBITDA is $-18.365M (high $-15.006M, low $-21.723M), average net income is $-72.321M (high $-68.904M, low $-75.738M), average SG&A $6.16M (high $7.14M, low $5.19M), and average EPS is $-14.49 (high $-14.49, low $-14.49). CDTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.51M (high $1.51M, low $1.51M), average EBITDA is $-1.115M (high $-1.115M, low $-1.115M), average net income is $-62.615M (high $-62.615M, low $-62.615M), average SG&A $919.34K (high $919.34K, low $919.34K), and average EPS is $-13.72 (high $-13.72, low $-13.72).
Did the CDTX's actual financial results beat the analysts' financial forecasts?
Based on Cidara Therapeutics's last annual report (Dec 2022), the company's revenue was $64.29M, beating the average analysts forecast of $51.01M by 26.03%. Apple's EBITDA was $-29.718M, missing the average prediction of $-61.897M by -51.99%. The company's net income was $-29.799M, missing the average estimation of $-62.853M by -52.59%. Apple's SG&A was $18.49M, missing the average forecast of $29.91M by -38.20%. Lastly, the company's EPS was $-0.43, missing the average prediction of $-14.213 by -96.97%. In terms of the last quarterly report (Sep 2023), Cidara Therapeutics's revenue was $12.72M, beating the average analysts' forecast of $8.14M by 56.25%. The company's EBITDA was $-8.555M, beating the average prediction of $-6.016M by 42.19%. Cidara Therapeutics's net income was $-8.172M, missing the average estimation of $-13.691M by -40.31%. The company's SG&A was $3.56M, missing the average forecast of $4.96M by -28.29%. Lastly, the company's EPS was $-0.09, missing the average prediction of $-3 by -97.00%